Comment by
Rumpl3StiltSkin on May 25, 2022 2:21pm
And this is still including the non-optimized first dozen patients? Right? So I think the market will take that into consideration, also. In time.
Comment by
Eoganacht on May 25, 2022 2:38pm
Hi Pandora - I think the majority of the NR patients are the first 12 undertreated patients.
Comment by
Pandora on May 25, 2022 2:44pm
Thanks Eoganacht -- haven't noticed if that is a clarifying point that is included in the reports. We'll have to see how the next report comes out. In my opinion it would be a positive to clarify it as opposed to having people just see 37% NR.
Comment by
ScienceFirst on May 25, 2022 3:28pm
Eoganacht ... What your CR potential numbers show is not only high numbers (60%-75%), despite 12 underdosed patients, but also quite consistent efficacy numbers, no matter the category (90, 180, 270, 360, 450). And this consistency confirms that our technology destroys instantly, instead of just shrinking the tumors. This is huge!
Comment by
BlueFranky on May 25, 2022 4:22pm
Science, that might be your most compelling post yet!